This book aims to bring together the current research and discussions surrounding bladder cancer management. New technologies and therapeutic agents have become increasingly effective at treating urothelial bladder cancer and have created a range of opportunities to change the ways in which the disease is treated. Chapters cover the changes in adjuvant treatment, confocal laser endomicroscopy, and the roles of oncologists, pathologists, and radiotherapists in managing bladder cancer. 

Treating Urothelial Bladder Cancer is particularly relevant to urologists, oncologists, and radiotherapists, but is also applicable to practitioners, geriatricians, and public health managers due to its multidisciplinary approach to bladder cancer management.

<p></p><p>Preface

Part I: Bladder cancer diagnosis
Imaging and bladder cancer: can we do better?
Optical improvements in bladder cancer diagnosis: seeing better for a better management
Enhancing the quality of transurethral resection: the importance of a complete TURB and the en-bloc resection
Active surveillance for low risk non-muscle invasive bladder cancer
Part II: Non-muscle invasive bladder cancer
How good we are to predict the outcomes of non-muscle invasive bladder cancer?
Adjuvant treatment: old and new immunotherapy in non-muscle invasive bladder cancer
The role of new experimental conservative therapies for high risk non-muscle invasive bladder cancer. Could we trust them?
Part III: Muscle invasive bladder cancer
Is there still a role for radical cystectomy?
Minimally invasive radical cystectomy and its role in the treatment of bladder cancer patients. Myth or reality?
Neoadjuvant vs adjuvant chemotherapy: which is right?
Radiotherapy for the treatment of muscle invasive bladder cancer
Immunotherapy and new combinations
Part IV: A view on the future
The role of urologist
The role of pathologist
The role of medical oncologist
The role of radiotherapist.</p><br><p></p>